Reviewed by Peptide Treatments Medical Advisory Board
CagriSema: Side Effects & Safety
Known side effects, safety considerations, and adverse reaction data for CagriSema.
Back to CagriSema overviewData source: Side effect data comes from clinical trials, preclinical research, and anecdotal reports. No FDA-approved labeling exists for this compound.
Reported Side Effects (7 items)
| # | Side Effect |
|---|---|
| 1 | Nausea (38-45%) |
| 2 | Diarrhea (20-25%) |
| 3 | Vomiting (14-18%) |
| 4 | Constipation (16-20%) |
| 5 | Injection site reactions (5-8%) |
| 6 | Pancreatitis (0.3-0.4%, consistent with semaglutide class) |
| 7 | Gallbladder disease (1.0-1.5%) |
Known Drug Interactions
Important: Only documented and contraindicated interactions are shown here. View all interactions including theoretical →
| Drug | Classification | Mechanism |
|---|---|---|
| Other GLP-1 agonists | Contraindicated | Duplicative GLP-1 receptor agonism — do not combine |
| Pramlintide (amylin analogs) | Contraindicated | Duplicative amylin receptor agonism — increased amylin effect |
| Insulin | Documented | Increased hypoglycemia risk — reduce insulin dose by 20% |
| Sulfonylureas | Documented | Increased hypoglycemia risk — reduce sulfonylurea dose by 50% |